Role of Statistical Random-Effects Linear Models in Personalized Medicine
Some empirical studies and recent developments in pharmacokinetic theory suggest that statistical random-effects linear models are valuable tools that allow describing simultaneously patient populations as a whole and patients as individuals. This remarkable characteristic indicates that these models may be useful in the development of personalized medicine, which aims at finding treatment regimes that are appropriate for particular patients, not just appropriate for the average patient. In fact, published developments show that random-effects linear models may provide a solid theoretical framework for drug dosage individualization in chronic diseases. In particular, individualized dosages computed with these models by means of an empirical Bayesian approach may produce better results than dosages computed with some methods routinely used in therapeutic drug monitoring. This is further supported by published empirical and theoretical findings that show that random effects linear models may provide accurate representations of phase III and IV steady-state pharmacokinetic data, and may be useful for dosage computations. These models have applications in the design of clinical algorithms for drug dosage individualization in chronic diseases; in the computation of dose correction factors; computation of the minimum number of blood samples from a patient that are necessary for calculating an optimal individualized drug dosage in therapeutic drug monitoring; measure of the clinical importance of clinical, demographic, environmental or genetic covariates; study of drug-drug interactions in clinical settings; the implementation of computational tools for web-site-based evidence farming; design of pharmacogenomic studies; and in the development of a pharmacological theory of dosage individualization.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Current pharmacogenomics and personalized medicine - 10(2012), 1 vom: 10. März, Seite 22-32 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Diaz, Francisco J [VerfasserIn] |
|---|
| Themen: |
Chronic diseases |
|---|
| Anmerkungen: |
Date Revised 18.03.2024 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM225579170 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM225579170 | ||
| 003 | DE-627 | ||
| 005 | 20240318232526.0 | ||
| 007 | tu | ||
| 008 | 231224s2012 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM225579170 | ||
| 035 | |a (NLM)23467392 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Diaz, Francisco J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of Statistical Random-Effects Linear Models in Personalized Medicine |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Some empirical studies and recent developments in pharmacokinetic theory suggest that statistical random-effects linear models are valuable tools that allow describing simultaneously patient populations as a whole and patients as individuals. This remarkable characteristic indicates that these models may be useful in the development of personalized medicine, which aims at finding treatment regimes that are appropriate for particular patients, not just appropriate for the average patient. In fact, published developments show that random-effects linear models may provide a solid theoretical framework for drug dosage individualization in chronic diseases. In particular, individualized dosages computed with these models by means of an empirical Bayesian approach may produce better results than dosages computed with some methods routinely used in therapeutic drug monitoring. This is further supported by published empirical and theoretical findings that show that random effects linear models may provide accurate representations of phase III and IV steady-state pharmacokinetic data, and may be useful for dosage computations. These models have applications in the design of clinical algorithms for drug dosage individualization in chronic diseases; in the computation of dose correction factors; computation of the minimum number of blood samples from a patient that are necessary for calculating an optimal individualized drug dosage in therapeutic drug monitoring; measure of the clinical importance of clinical, demographic, environmental or genetic covariates; study of drug-drug interactions in clinical settings; the implementation of computational tools for web-site-based evidence farming; design of pharmacogenomic studies; and in the development of a pharmacological theory of dosage individualization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic diseases | |
| 650 | 4 | |a dosage individualization | |
| 650 | 4 | |a drug mixed linear models | |
| 650 | 4 | |a effect sizes | |
| 650 | 4 | |a empirical Bayesian feedback | |
| 650 | 4 | |a evidence farms | |
| 650 | 4 | |a pharmacokinetic modeling | |
| 650 | 4 | |a random-effects linear models. | |
| 700 | 1 | |a Yeh, Hung-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a de Leon, Jose |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmacogenomics and personalized medicine |d 2008 |g 10(2012), 1 vom: 10. März, Seite 22-32 |w (DE-627)NLM187562679 |x 1875-6921 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2012 |g number:1 |g day:10 |g month:03 |g pages:22-32 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2012 |e 1 |b 10 |c 03 |h 22-32 | ||